The present invention relates to an antitumor drug comprising β-cyclodextrin or a derivative thereof. In addition, the present invention relates to β-cyclodextrin characterized by the combination use with another antitumor drug, an antitumor drug comprising the combination, a combination therapy with β-cyclodextrin and another antitumor drug for treating cancer or the like, etc.
